Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

Su Cho Kang, Shik Lee Joong, Hoon Cho Nam, Kyeongmee Park, Sik Ham Won, Deuk Choi Young

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND. Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS. Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS. Gene amplification of EGFR was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS. EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis.

Original languageEnglish
Pages (from-to)803-808
Number of pages6
JournalProstate
Volume68
Issue number8
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Gene Amplification
Epidermal Growth Factor Receptor
Prostatic Neoplasms
Hormones
Mutation
Exons
erbB-1 Genes
Sequence Deletion
Fluorescence In Situ Hybridization

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Kang, Su Cho ; Joong, Shik Lee ; Nam, Hoon Cho ; Park, Kyeongmee ; Won, Sik Ham ; Young, Deuk Choi. / Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. In: Prostate. 2008 ; Vol. 68, No. 8. pp. 803-808.
@article{6d8b526021ee4022918fe2a8a8760889,
title = "Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer",
abstract = "BACKGROUND. Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS. Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS. Gene amplification of EGFR was observed in 6 (30{\%}) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS. EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis.",
author = "Kang, {Su Cho} and Joong, {Shik Lee} and Nam, {Hoon Cho} and Kyeongmee Park and Won, {Sik Ham} and Young, {Deuk Choi}",
year = "2008",
month = "6",
day = "1",
doi = "10.1002/pros.20743",
language = "English",
volume = "68",
pages = "803--808",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "8",

}

Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. / Kang, Su Cho; Joong, Shik Lee; Nam, Hoon Cho; Park, Kyeongmee; Won, Sik Ham; Young, Deuk Choi.

In: Prostate, Vol. 68, No. 8, 01.06.2008, p. 803-808.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

AU - Kang, Su Cho

AU - Joong, Shik Lee

AU - Nam, Hoon Cho

AU - Park, Kyeongmee

AU - Won, Sik Ham

AU - Young, Deuk Choi

PY - 2008/6/1

Y1 - 2008/6/1

N2 - BACKGROUND. Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS. Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS. Gene amplification of EGFR was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS. EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis.

AB - BACKGROUND. Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS. Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS. Gene amplification of EGFR was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS. EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis.

UR - http://www.scopus.com/inward/record.url?scp=45349087172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349087172&partnerID=8YFLogxK

U2 - 10.1002/pros.20743

DO - 10.1002/pros.20743

M3 - Article

C2 - 18302229

AN - SCOPUS:45349087172

VL - 68

SP - 803

EP - 808

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 8

ER -